Cautions
Information on adverse effects of propofol has been obtained principally from controlled clinical trials and worldwide postmarketing experience with the drug. The studies were conducted using various premedications, other anesthetic or sedative agents, and a range of lengths of surgical or diagnostic procedures. Most adverse effects were mild and transient. In adults, the adverse effect profile in patients undergoing monitored anesthesia care (MAC) sedation was similar to that of patients undergoing anesthesia, although more severe adverse respiratory effects (e.g., cough, upper airway obstruction, apnea, hypoventilation, dyspnea) were reported in those undergoing MAC sedation. In addition, the adverse effect profile in pediatric patients 6 days to 16 years of age undergoing anesthesia was similar to that of adults receiving propofol for anesthesia, although apnea may occur more frequently in children than in adults.
•Cardiovascular Effects
Propofol is a cardiovascular depressant with effects similar to or greater than those associated with other IV anesthetic induction agents. The main adverse cardiovascular effect of propofol during induction anesthesia is hypotension, with 30% or more decreases in both systolic and diastolic blood pressure. Concomitant use of propofol with an opiate agonist appears to increase the risk of severe hypotension. Administration of additional fluids and a cautious rate of IV infusion may help to prevent propofol-induced hypotension. Severe hypotensive effects may be alleviated by medical intervention. (See Cautions: Precautions and Contraindications.)
In clinical trials in patients undergoing anesthesia or MAC sedation, hypotension or arrhythmias (e.g., bradycardia, tachycardia) were reported in 3–10 or 1–3% of adults, respectively, while hypotension, hypertension, or arrhythmias (e.g., tachycardia) were reported in 17, 8, or 1.2–1.6% of pediatric patients undergoing anesthesia, respectively. In less than 1% of adults, ECG abnormalities, bigeminy, atrial arrhythmias, atrial premature complexes (APCs, PACs), ventricular premature complexes (VPCs, PVCs), and syncope, possibly associated with use of propofol, have been reported. Although a causal relationship to propofol has not been established, atrial fibrillation, atrioventricular (AV) heart block, bundle branch block, cardiac arrest, edema, extrasystole, hypertension, myocardial infarction, myocardial ischemia, ST-segment depression, supraventricular tachycardia, and ventricular fibrillation were reported in clinical trials in less than 1% of adults receiving propofol for anesthesia or MAC sedation.
In clinical trials in intubated, mechanically ventilated patients undergoing sedation with propofol in a critical care setting (e.g., an ICU), hypotension, bradycardia, and decreased cardiac output were reported in 26, 1–3, and 1–3% of patients, respectively. Although a causal relationship to propofol has not been established, arrhythmias (e.g., ventricular tachycardia), atrial fibrillation, bigeminy, cardiac arrest, extrasystole, and right-sided heart failure have been reported in less than 1% of adults receiving propofol for sedation in a critical care setting.
•Respiratory Effects
Propofol can depress respiration, and induction anesthesia frequently is associated with apnea. In clinical trials in 1573 adults receiving propofol for induction of anesthesia, duration of apnea was less than 30, 30–60, and more than 60 seconds in 7, 24, and 12% of patients, respectively. In addition, in clinical trials in 218 pediatric patients (neonates and children 16 years of age and younger) receiving 1- to 3.6-mg/kg doses of rapid IV propofol injections for induction of anesthesia, duration of apnea was less than 30, 30–60, and more than 60 seconds in 12, 10, and 5% of patients, respectively. Overall, apnea was reported in 1–3% of adult patients undergoing anesthesia or MAC sedation. The respiratory depressant effects of propofol appear to be similar to those of other IV induction anesthetics; however, the incidence and duration of apnea associated with propofol may be greater. During maintenance anesthesia, propofol may cause decreased ventilation, usually associated with increased carbon dioxide tension (PaCO2), the likelihood of which depends on the rate of administration of propofol and other concomitantly used drugs (e.g., opiates, sedatives).
In clinical trials, wheezing and cough, possibly associated with use of propofol, were reported in less than 1% of adults undergoing anesthesia or MAC sedation. Although a causal relationship to propofol has not been established, hypoxia, laryngospasm, bronchospasm, laryngismus, pulmonary edema, burning of the throat, dyspnea, hiccups, hyperventilation, hypoventilation, pharyngitis, sneezing, tachypnea, and upper airway obstruction were reported in less than 1% of adults receiving propofol for anesthesia or MAC sedation.
Although the respiratory depressant effects of propofol are not clinically important during mechanical ventilation, such effects may be important during the weaning process. Respiratory acidosis during weaning has been reported in 3–10% of adults undergoing sedation in a critical care setting. Decreased pulmonary function, possibly related to use of propofol, has been reported in less than 1% of adults undergoing sedation in a critical care setting, while hypoxia occurred in less than 1% of such adults; however, a causal relationship to the drug has not been established.
•Nervous System Effects
Involuntary movement has been reported in 3–10% of adults receiving propofol for anesthesia or MAC sedation, while this effect occurred in 17% of pediatric patients undergoing anesthesia. Hypertonia and/or dystonia, paresthesia, anticholinergic syndrome, agitation, chills, delirium, dizziness, and somnolence, possibly related to the use of propofol, have been reported in less than 1% of adults undergoing anesthesia or MAC sedation; in addition, abnormal dreams, increased sexual mood, anxiety, bucking/jerking/thrashing, confusion, shivering, clonic and/or myoclonic movement, asthenia, combativeness, confusion, depression, emotional lability, excitement, euphoria, fatigue, hallucinations, headache, hysteria, insomnia, moaning, neuropathy, opisthotonos, rigidity, seizures, somnolence, tremor, and twitching were reported in less than 1% of such adults, but causal relationship to propofol has not been established.
In less than 1% of adults undergoing sedation in a critical care setting, agitation, possibly related to the use of propofol, has been reported. In addition, chills and/or shivering, intracranial hypertension, seizures, somnolence, and abnormal thinking have been reported in less than 1% of such patients, although a causal relationship to propofol has not been established.
•Local Effects
Pain at the injection site occurs frequently (in up to 70% of patients) following peripheral IV administration of propofol. Pain at the injection site can be minimized in adults and children if the larger veins of the forearm or antecubital fossa rather than hand veins are used and by administering 1 mL of a 1% solution of IV lidocaine prior (30–120 seconds) to IV administration of propofol. For prevention of pain at the propofol injection site, other methods, including prior administration of opiates or metoclopramide, prior application of a tourniquet, topical nitroglycerin or a local anesthetic cream, or administration of propofol at low temperatures (4–5°C) also have been used. Intra-arterial injection in animals did not result in adverse local tissue effects and while pain was reported in patients who received inadvertent intra-arterial injection of propofol, there was no evidence of major sequelae. In animals, injection of propofol into subcutaneous or perivascular tissues was associated with minimal tissue reaction. Local pain, swelling, blisters and/or tissue necrosis has been reported rarely following inadvertent extravasation in postmarketing surveillance of propofol. The manufacturers state that in clinical trials, burning, stinging, or pain at the injection site was reported in 17.6% of adults undergoing anesthesia or MAC sedation and in 10% of pediatric patients. Phlebitis, thrombosis, and pruritus, possibly related to use of propofol, were reported in less than 1% of adults, while urticaria and/or pruritus and redness/discoloration were reported in less than 1% of such adults, but a causal relationship to the drug has not been established